Hyperscale Data, Inc. filed a Form 8-K with the SEC on November 9, 2026, disclosing that on November 6, 2026, the company entered into a note purchase agreement with an institutional investor covering a series of convertible promissory notes with aggregate principal up to …
Roman DBDR Acquisition Corp. II filed a Form 8-K on November 9, 2026, disclosing the November 4, 2026 resignation of board member Randolph C. Read and the subsequent appointment of two directors to committee roles.
SPACCircle Acquisition Corp. filed a Form 8-K on November 9, 2026, disclosing that holders of its IPO units may elect to separately trade the component Class A ordinary shares, warrants, and rights beginning November 10, 2026.
TruGolf Holdings, Inc. filed a Form 8-K/A (Amendment No. 2) on November 6, 2026, supplementing its prior current reports to include audited and unaudited financial statements of Polymath Research Inc. and unaudited pro forma combined financial information following the October 8, 2026 acquisition of …
Datavault AI Inc. filed a Form 8-K on November 9, 2026, disclosing a series of executive officer appointments and board leadership changes effective November 6, 2026.
Laredo Oil, Inc. filed a Form 8-K on November 9, 2026, reporting that stockholders approved by written consent on October 29, 2026, an amendment to increase the company's authorized shares of common stock from 120,000,000 to 350,000,000.
FTAI Aviation Ltd. filed an 8-K on November 9, 2026, disclosing that its subsidiary FTAI Aviation Investors LLC issued $1.0 billion aggregate principal amount of 7.125% Senior Notes due 2034 on November 6, 2026.
Valion Bio, Inc. filed a Form 8-K on November 9, 2026, reporting that on November 6, 2026, it completed a closing under its Series B Non-Voting Convertible Preferred Stock purchase agreement with 3i, LP, raising $700,000 through the issuance of preferred shares and warrants.
Cabaletta Bio, Inc. filed a current report on November 9, 2026, disclosing new Phase 1/2 clinical data for rese-cel (resecabtagene autoleucel, formerly known as CABA-201) presented at the American College of Rheumatology Convergence 2026, covering outcomes across four autoimmune diseases.
Flag Ship Acquisition Corp. filed an 8-K on November 9, 2026, reporting the results of its annual general meeting of shareholders held on November 6, 2026, at which shareholders voted on director elections, auditor ratification, and an adjournment proposal.